Colonization of mucosal respiratory surfaces is a prerequisite for the human pathobiont Streptococcus pneumoniae (the pneumococcus) to cause severe invasive infections. The arsenal of pneumococcal adhesins interacts with a multitude of extracellular matrix proteins. A paradigm for pneumococci is their interaction with the adhesive glycoprotein fibronectin, which facilitates bacterial adherence to host cells. Here, we deciphered the molecular interaction between fibronectin and pneumococcal fibronectinbinding proteins (FnBPs) PavA and PavB respectively. We show in adherence and binding studies that the pneumococcal interaction with fibronectin is a non-human specific trait. PavA and PavB target at least 13 out of 15 type III fibronectin domains as demonstrated in ligand overlay assays, surface plasmon resonance studies and SPOT peptide arrays. Strikingly, both pneumococcal FnBPs recognize similar peptides in targeted type III repeats. Structural comparisons revealed that the targeted type III repeat epitopes cluster on the inner strands of both b-sheets forming the fibronectin domains. Importantly, synthetic peptides of FnIII 1 , FnIII 5 or FnIII 15 bind directly to FnBPs PavA and PavB respectively. In conclusion, our study suggests a common pattern of molecular interactions between pneumococcal FnBPs and fibronectin. The specific epitopes recognized in this study can potentially be tested as antimicrobial targets in further scientific endeavours.
Summary
Colonization of mucosal respiratory surfaces is a prerequisite for the human pathobiont Streptococcus pneumoniae (the pneumococcus) to cause severe invasive infections. The arsenal of pneumococcal adhesins interacts with a multitude of extracellular matrix proteins. A paradigm for pneumococci is their interaction with the adhesive glycoprotein fibronectin, which facilitates bacterial adherence to host cells. Here, we deciphered the molecular interaction between fibronectin and pneumococcal fibronectinbinding proteins (FnBPs) PavA and PavB respectively. We show in adherence and binding studies that the pneumococcal interaction with fibronectin is a non-human specific trait. PavA and PavB target at least 13 out of 15 type III fibronectin domains as demonstrated in ligand overlay assays, surface plasmon resonance studies and SPOT peptide arrays. Strikingly, both pneumococcal FnBPs recognize similar peptides in targeted type III repeats. Structural comparisons revealed that the targeted type III repeat epitopes cluster on the inner strands of both b-sheets forming the fibronectin domains. Importantly, synthetic peptides of FnIII 1 , FnIII
Introduction
Streptococcus pneumoniae, a Gram-positive bacterium growing in pairs or chains, resides typically as a harmless commensal on mucosal surfaces of the human upper respiratory tract. Despite colonizing the human host asymptomatically under normal conditions, the pneumococcus is a pathobiont possessing a remarkably high potential to cause non-invasive and invasive disease respectively (Cartwright, 2002; van der Poll and Opal, 2009; Mook-Kanamori et al., 2011) . Upon colonization the pneumococcus may transmigrate into the lungs and gain access to sterile niches of the human body i.e., blood, cerebrospinal fluid (CSF), pleural fluid or pericardial fluid (Bogaert et al., 2004; Randle et al., 2011; Gamez and Hammerschmidt, 2012) . This high virulence potential is attributed to an arsenal of colonization and virulence factors (Orihuela et al., 2004; Bergmann and Hammerschmidt, 2006; Hammerschmidt, 2006; Kadioglu et al., 2008; Voss et al., 2012) mostly exposed on the pneumococcal cell surface. Several of these factors, which are in general referred to as adhesins or immune evasion factors, not only contribute individually and in a concerted action to the efficient pneumococcal adherence to various host tissues, but also allow successful evasion from host innate immune responses (Agarwal et al., 2010 (Agarwal et al., , 2012 Voss et al., 2012 Voss et al., , 2013 Blom et al., 2014; Hilleringmann et al., 2015; Kohler et al., 2015) . A major proportion of pneumococcal adhesins belong to the family of microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). These MSCRAMMs are of utmost importance for several Gram-positive pathogens including Staphylococcus aureus, Streptococcus pyogenes and S. pneumoniae by exploiting adhesive glycoproteins of the extracellular matrix (ECM) for their attachment to host epithelial or endothelial cells and immune evasion mechanisms (Fowler et al., 2000; Singh et al., 2012; Voss et al., 2012; Yamaguchi et al., 2013) . ECM or serum proteins like fibronectin (Fn), fibrinogen, vitronectin, plasminogen, factor H and the matricellular glycoprotein thrombospondin-1 are produced by various host cells and platelets, respectively (Glasgow and Colman, 1984; Gutman et al., 1986; Raugi and Lovett, 1987; Katz and Strunk, 1988; Schvartz et al., 1999; Brouwer et al., 2016) and are often used as a molecular bridge by the pathogens to link them with host cells to facilitate colonization and initiate dissemination into the host (Patti et al., 1994; Talay et al., 2000; Bergmann et al., 2009; Henderson et al., 2011; Voss et al., 2012; Walden et al., 2015) .
Fibronectin, a high molecular weight adhesive glycoprotein, is endowed with a broad spectrum of functions ranging from ECM formation, cell differentiation and growth to wound healing (Mosher and Furcht, 1981) and exists in two forms in the human body: as soluble 440 kDa compact dimer in plasma (so-called cold-insoluble globulin) and as a multimeric fibrillar form in connective tissue and basement membranes (To and Midwood, 2010 , 2011a , 2011b . The concentration in human plasma is in the range of 200-700 mg/ml (To and Midwood, 2011b) . The multi-domain molecule Fn contains three types of repetitive domains with independent three-dimensional modular structures. The Fn monomer is typically composed of 12 type I repeats (40 amino acid residues each), 2 type II repeats (60 amino acids each) and 15-17 type III repeats (90 amino acid residues each) (Pankov and Yamada, 2002) . Owing to the presence of intramolecular disulfide bonds type I and type II repeats are structurally rigid, in contrast to the conformationally flexible b-barrels of type III repeats, which are devoid of these linkages and thus suitable to be involved in Fn fibrillogenesis (Wierzbicka-Patynowski and Schwarzbauer, 2003; Singh et al., 2010) . The repetitive domains of fibronectin have multiple binding sites for various biological ligands including cellular integrins, bacterial FnBPs, proteoglycans, heparin, other ECM molecules and fibronectin itself (self-association), that account for the multifunctional nature of Fn (Mosher and Furcht, 1981; Pankov and Yamada, 2002) .
Fibronectin binding proteins (FnBPs) form a sub-class of microbial MSCRAMMs that specifically exploit the adhesive glycoprotein Fn as a molecular bridge to adhere effectively to host cells. This in turn facilitates bacterial internalization by eukaryotic cells, because Fn binds preferentially to integrins, thereby indirectly modulating the host cytoskeletal machinery via activation of signal transduction cascades (Patti et al., 1994; Talay et al., 2000; Christie et al., 2002; Schwarz-Linek et al., 2003; Agerer et al., 2005; Jakubovics et al., 2009; Oviedo-Boyso et al., 2011) . FnBPs, produced by a variety of pathogenic bacteria including S. aureus, Group A, B and G streptococci, Borrelia burgdorferi, Bartonella henselae, Moraxella catarrhalis and Campylobacter jejuni are exploited to interact indirectly with host cellular receptors via the fibronectin mechanism (Talay et al., 1991; Patti et al., 1994; Courtney et al., 1996; Konkel et al., 1997; Raibaud et al., 2005) . Pneumococcal proteins interacting with fibronectin are the pneumococcal adherence and virulence factor A (PavA) and B (PavB), the endopeptidase O, and PfbA (Holmes et al., 2001; Bumbaca et al., 2004; Pracht et al., 2005; Jedrzejas, 2007; Yamaguchi et al., 2008; Jensch et al., 2010; Voss et al., 2012; Agarwal et al., 2013; Hilleringmann et al., 2015) .
The classical structural criterion of MSCRAMMs, possessing a C-terminally located LPXTG anchoring motif for the sortase-dependent covalent linkage to the peptidoglycan (Patti et al., 1994) , is fulfilled by PavB and PfbA, but not by PavA and Endo O. PavA and Endo O belong to the non-classical surface proteins (NCSP), a family of proteins found on the pneumococcal cell surface despite lacking a signal peptide and a typical motif for covalent or non-covalent anchorage (Voss et al., 2012) . PavA and PavB are encoded by genes of the core genome and are expressed in virtually all pneumococci (Holmes et al., 2001; Jensch et al., 2010) . In its mature part, PavB consists of characteristic repetitive domains referred to as Streptococcal SUrface REpeats (SSURE), and each highly conserved core SSURE consists of 152 amino acids (Bumbaca et al., 2004; Jensch et al., 2010) . The number of these repeats is straindependent and hence, responsible for the variation of the molecular weight across different pneumococcal strains. Other streptococcal species such as Streptococcus agalactiae, Streptococcus gordonii, Streptococcus mitis and Streptococcus mutans produce homologues of PavB and SSURE (Jedrzejas, 2007; Jensch et al., 2010) . PavB is a pneumococcal colonization factor and has the capability to interact directly via a yet unknown host cell receptor or indirectly via human ECM or serum proteins like fibronectin, plasminogen or thrombospondin with eukaryotic cells (Bumbaca et al., 2004; Jedrzejas, 2007; Jensch et al., 2010; Binsker et al., 2015) .
PavA, as a member of the NCSP, is secreted and exposed on the pneumococcal cell surface by a so far unknown mechanism. PavA binds in a heparin-sensitive manner to immobilized fibronectin, and homologues of PavA are identified in S. gordonii (FbpA; 74% identity) and S. pyogenes (Fbp54; 67% identity) (Holmes et al., 2001) . The deficiency of PavA causes a substantial attenuation, resulting in an inability to cause pneumonia, septicaemia or meningitis in mouse infection models and loss of adherence to respiratory epithelial cells and human brain microvascular endothelial cells (Holmes et al., 2001; Pracht et al., 2005; Kadioglu et al., 2010) . Strikingly, exogenously added recombinant PavA (rPavA) restores the wild type in a pavA-mutant and pavA-mutants covered with rPavA escape phagocytosis and induce a cytokine profile similar to wild-type pneumococci (Noske et al., 2009) . FBPS, a homologue of PavA with 74% identity, reveals an a/b and an a domain in its N-terminal half and an a domain with two very long helices and an a/b domain in its C-terminal half (Musyoki et al., 2016) .
Pneumococcal binding to immobilized fibronectin is heparin-sensitive and binding of pneumococcal PavA, PavB, enolase and PfbA to fibronectin is also heparin sensitive (van der Flier et al., 1995; Holmes et al., 2001; Pracht et al., 2005; Yamaguchi et al., 2008; Jensch et al., 2010) . Pneumococci target most likely only the C-terminal part of the fibronectin molecule; however, the molecular interaction of pneumococcal FnBPs with the C-terminal Fn type III (FnIII) repeats has not been assessed so far. This study revealed in particular that pneumococcal recruitment of plasma fibronectin and binding to the immobilized form of fibronectin via its FnBPs PavA and PavB is mediated by defined interactions with domains within the FnIII repeats. Strikingly, the tested FnBPs show a similar pattern of interactions with FnIII repeats as demonstrated via direct proteinprotein interactions and peptide-array analysis.
Results

Pneumococcal interaction with fibronectin is a non-human specific trait
The ability of S. pneumoniae to recruit soluble, plasmaderived fibronectin from humans was assessed. Binding of plasma-derived soluble fibronectin was demonstrated by flow cytometry, thereby revealing a dose-dependent effect. The amount of bacterial-bound fibronectin correlated with the percentage of used human plasma in the binding experiments (Fig. 1) . Immunoblot analysis of pneumococci incubated with increasing amounts of human plasma further indicated that pneumococci are able to recruit soluble fibronectin when present in plasma (Fig. 1B) .
Pneumococci are human-specific pathogens, however, the interaction of pneumococcal PspC with the ectodomain of the polymeric immunoglobulin receptor (pIgR) is the only human species-specific interaction known so far (Hammerschmidt et al., 2000) . To decipher whether the interaction of pneumococci with fibronectin is a speciesspecific phenomenon, bacteria were incubated with plasma from other species such as bovine, pig, goat, alpaca and weasel. Binding of plasma fibronectin from these species was indicated by immunoblot and flow cytometric analysis suggesting that the recruitment of plasma fibronectin is a non-species specific trait. Remarkably, the lowest binding activity was demonstrated for bovine fibronectin ( Fig. 1B and C) . This is in accordance with our observation that pneumococci did not recruit detectable amounts of fibronectin from fetal bovine serum used in the following adherence assays, as verified by flow cytometry and immunoblot analysis (data not shown).
Binding of purified fibronectin by pneumococci
Pneumococci were also compared for their efficiency to bind soluble plasma (pFn) or cellular fibronectin (cFn) from humans. Immunoblot analysis post-incubation of pneumococci with pFn or cFn demonstrated a dosedependent binding of both fibronectin forms (Fig. 1D) . The non-species-specificity of Fn-binding was further investigated by incubating pneumococci with purified human pFn and bovine pFn. Similar to the results of bovine plasma (Fig. 1B and C) , pneumococci bound pure bovine fibronectin, although with a substantial lower efficiency than human pFn and cFn (Fig. 1D) . Hence, in lieu of binding bovine fibronectin or fibronectin from other species, pneumococci seem to interact preferentially with human fibronectin.
Host-cell bound fibronectin enhances pneumococcal adherence
To assess the role of human pFn and cFn in pneumococcal attachment to host epithelial cells, nasopharyngeal Detroit 562 epithelial cells (D562 cells) or pneumococci were treated with human pFn before starting the infection. Two different approaches were conducted and analyzed by immunofluorescence microscopy. In one series of experiments host cell unbound pFn was removed prior infection with pneumococci, while in the other series the infection was performed in the presence of the exogenously added pFn. In the presence of exogenously added pFn pneumococcal adherence to Detroit 562 cells was not affected (Fig.  2A) . In contrast, pre-incubation of D562 cells and removal of unbound pFn resulted in a significant increase in pneumococcal adherence to D562 cells compared with untreated cells (Fig. 2A) . Importantly, pre-incubation of pneumococci with fibronectin results in bacterial adherence that is similar to the level of the control assay and hence, reached in the absence of fibronectin ( Fig. 2A) . Because adherence of pneumococci to D562 cells was only increased after preincubation with pFn and removal of unbound pFn prior to the infection, all the other experiments assessing the effect of Fn on pneumococcal adherence to host cells were conducted in this particular way.
To compare the efficiency of pFn to enhance pneumococcal attachment to epithelial cells with the potential effect of cFn, nasopharyngeal D562 cells were incubated with different amounts of pFn or cFn prior to the bacterial infection. The number of adherent bacteria was determined by double immune fluorescence staining. Treatment of D562 cells with 2 mg human pFn or cFn per well resulted in significant increased levels of bacterial adherence (Fig. 2B) . The number of adherent pneumococci on D562 cells reached a maximum after preincubation of the cells with 2 mg pFn or cFn per monolayer and decreased slightly after pre-incubation of Streptococcus pneumoniae 35A were incubated with different amounts of plasma (human and bovine) or with different forms of purified fibronectin. Pneumococcal bound fibronectin was also detected by flow cytometry using anti-fibronectin IgG followed by FITC-labeled secondary antibody (A and C). In addition, whole cell lysates of pretreated bacteria were separated by SDS-PAGE and bound fibronectin was epithelial cells with 5 mg cFn or pFn ( Fig. 2B and D) . This effect might be attributed to the steric hindrance endowed by the increased amount of fibronectin fibrils. However, the fibronectin-mediated increase in bacterial adherence remained significant. Furthermore, the fibronectin-mediated adherence mechanism was also demonstrated for lung epithelial cells A549, HEp-2 cells (Fig. 2C ) and human brain microvascular endothelial cells (data not shown). Similar to the human forms of Fn also bovine pFn enhanced significantly pneumococcal adherence to host cells as shown for A549, HEp-2 and D562 epithelial cells (Fig. 2C ). Taken together, both forms of human fibronectin, cFn and pFn, and also bovine Fn are able to enhance significantly pneumococcal adherence to various Fn-decorated host cells. Human epithelial cells were infected with pneumococci under two different experimental conditions. Either eukaryotic host cells were preincubated with purified human fibronectin or bacterial cells were pre-incubated with human fibronectin. Adherence pattern of pneumococci was assessed further in the presence of unbound human fibronectin or after washing the unbound fibronectin from the cells. The data represent the mean values of three independent experiments. SD was calculated by comparing the samples with Fn incubation with untreated samples. A. Host cell bound purified human fibronectin increases pneumococcal adherence to human nasopharyngeal cells Detroit 562 (washed cells), while the presence of fibronectin in adherence studies with unwashed cells and pneumococcal bound fibronectin (S.p. 35A) have no significant effect on bacterial adherence. B. Detroit 562 cells were infected with S. pneumoniae serotype 35A after incubating the cells with different amounts of human plasma or cellular fibronectin and depleting unbound fibronectin. The number of adherent bacteria per cell was determined by immunofluorescence microscopy. C. The effect of host cell bound human plasma fibronectin or bovine plasma fibronectin on pneumococcal adherence was tested using Detroit 562 cells, type II pneumocytes A549 and larynx carcinoma cells HEp-2. Host cells were pre-incubated with 5 mg human or bovine plasma fibronectin and pneumococcal adherence was quantified by immunofluorescence microscopy. D. Scanning electron microscopy showing the increase in pneumococcal adherence in the presence of host cell bound fibronectin. Detroit 562 cells were pre-incubated with 5 mg pFN.
Pneumococcal FnBPs PavA and PavB interact via C-terminal type III domains of human fibronectin
Pneumococcal PavA and PavB were shown to interact with immobilized human fibronectin; however, their impact on recruiting soluble human fibronectin as present in serum has not been investigated. To investigate this, far western ligand overlay assays were conducted in which pneumococcal PavA, its N-terminal 42 kDa fragment (PavA 42: the N-terminal half of PavA and the first long a-helix of the C-terminal half according to the PavA model based on FBPS, Supporting Information Fig. S1 ), and representative SSURE domains of PavB were immobilized on a nitrocellulose membrane followed by incubation with human plasma (Fig. 3A and Supporting Information Fig. S2A ). The full-length PavA was heterologously expressed and purified as maltose-binding protein (MBP) fusion protein, hence MBP was employed as a control protein to rule out false positive binding due to plasma protein binding to MBP. The FnBPA of S. aureus (Hauck and Ohlsen, 2006 ) was used as a positive control while pneumococcal enolase and BSA were used as negative controls. The results of these binding experiments revealed the ability of both pneumococcal FnBPs PavA and PavB to interact with soluble human plasma fibronectin (Fig. 3A) and moreover, both PavA proteins, full-length PavA (MBP-PavA) and PavA 42 , recruited human fibronectin from plasma (Fig. 3A) . Binding of Fn to PavB protein fragments seems to be dependent on the number of repetitive domains (Fig. 3A) , a finding similar to the interaction with immobilized Fn . SSURE 1-5 , representing the mature core domain of TIGR4 PavB , bound plasma-derived Fn with the highest efficiency followed by the PavB derivative SSURE 2 1 3 consisting of two repeats, while a single SSURE 2 domain showed a negligible efficiency to recruit the soluble form of human Fn from plasma ( Fig. 3A) . , biotinylatedHis 6 -PavA42 (50 mg/ml) (D) and biotinylated-His 6 -SSURE 2 1 3 (150 mg/ml) (D) respectively. Bound ligands were detected by using either a specific antiserum against PavA (1:500) followed by a secondary IgG conjugated with alkaline phosphatase (C) or streptavidin-AP conjugated antibody (D and E). Far western blotting indicated that PavA and PavB interact with human fibronectin via its C-terminal type III repeats as the N-terminal 70 kDa peptide showed binding neither to PavA nor to PavB. BSA was taken as a negative control.
To decipher the interaction domain(s) of pneumococcal FnBPs in the fibronectin molecule, purified fibronectin type III repeat (FnIII) (Fig. 3B and Supporting Information Fig. S2B ) fragments (Ohashi and Erickson, 2005) , which harbours the heparin-binding domain II (HBDII) of Fn.
Binding of PavA and PavB to FnIII repeats analyzed by surface plasmon resonance
To confirm the mode of interaction between pneumococcal FnBPs and FnIII repeats, full-length Fn, the N-terminal 70 kDa Fn domain and the aforementioned different FnIII repeats were employed in direct proteinprotein interaction analysis with pneumococcal FnBPs using the surface plasmon resonance (SPR) technique. Fibronectin and its subdomains were on the one hand used as ligands immobilized on the CM5 biosensor and on the other hand as analytes in their soluble form.
MBP-PavA, PavA 42 and PavB (SSURE 2 1 3 ) bound to immobilized hFn with different binding efficiencies. MBP, used as a control, did not bind to one of the immobilized ligands (Supporting Information Fig. S2 ). Pneumococcal PavA and PavA 42 bound to immobilized human Fn when used as analytes in nanomolar concentrations (0.0005 mM -0.025 mM) suggesting a higher affinity to hFn in comparison with PavB, which has to be used in a low micromolar concentration to bind to hFn. Importantly, the sensorgrams of PavA and PavA 42 were similar, suggesting that the C-terminal truncation in PavA has only a minor effect on the PavA-fibronectin interactions. SPR analysis revealed further that PavA, Pav 42 and PavB showed only a negligible binding to the immobilized N-terminal Fn 70 kDa fragment (Fig. 4) , confirming the 42 and His 6 -tagged SSURE 2 1 3 (PavB) to immobilized human plasma fibronectin (Millipore) and His 6 -tagged fibronectin fragments (FnIII) was analyzed by SPR. Fn and His 6 -tagged Fn domains were coated on the CM5 biosensor and used as ligands, while different concentrations of PavA, PavA 42 and SSURE 2 1 3 were used as analytes. Binding was assessed with a flow rate of 10 ml/min in PBS-Tween 20 (0.05%) using the indicated concentrations. MBP as analyte did not bind to Fn or FnIII repeats (Fig. S3) 
In the reverse approach MBP-PavA (PavA), His 6 -tagged PavA 42 and His 6 -tagged SSURE 2 1 3 (PavB) were used as ligands and immobilized on the CM5 biosensor. His 6 -FnIII domains, purified under native conditions, were used as analytes at a flow rate of 10 ml/min in PBS-Tween 20 (0.05%). When MBP-PavA was used as ligand the concentration for FnIII fragments ranged from 0.125 to 2mM, for PavA 42 the FnIII fragment concentrations ranged from 0.018 to 1.25 mM, while for PavB (SSURE 2 1 3 ) the Fn fragments were analyzed for their binding in the range between 0.075 and 5 mM. Changes in plasmon resonance are shown as relative response units (RUs) . The values of the control flow cell and the 0 mM data were subtracted from each sensorgram. Binding of FnIII repeats to immobilized MBP is shown in Fig. S3 . Table S5 ) with an overlap of twelve amino acids (shift of three aa). Peptides were generated on a cellulose membrane by the SPOT method. The peptide array was incubated with (A) MBP-PavA (50 mg/ml) or (B) His 6 -tagged SSURE 2 1 3 (150 mg/ml) representing PavB as a ligand. Bound ligands (MBP-PavA and SSURE 2 1 3 ) were detected using specific antisera followed by peroxidase conjugated secondary IgG. C. Overview of peptide sequences of identified PavA or PavB binding epitopes in FnIII repeats. 3: no positive peptide.
In this particular experimental approach MBP, used as control protein for MBP-PavA, bound soluble FnIII fragments albeit at a lower level than MBP-PavA (Supporting Information Fig. S3 (Fig. 5) .
Similar to the approach with immobilized FnIII repeats, lower binding activities to pneumococcal FnBPs were demonstrated for repeats possessing the RGD motif ( Fig. 5 and Supporting Information Tables S4-S6 ). However, the soluble forms of the latter mentioned FnIII repeats interacted more efficiently with PavA and PavB compared with the immobilized forms as higher RUs were measured. This apparent discrepancy is most likely the result of conformational differences and thus, the exposure of cryptic sites of these particular domains in soluble and immobilized forms are decisive for the interaction with PavA and PavB respectively.
Epitope mapping of binding sites of PavA and PavB within C-terminal type III repeats of human fibronectin
To further narrow down the binding motifs of PavA and PavB, respectively, in FnIII repeats, and to map the binding epitopes, we used a SPOT peptide array of chemically synthesized peptides (Frank, 1992; Bergmann et al., 2003) covering the complete FnIII region. The sequence of the FnIII 1-15 region was divided into 445 peptides, each comprising 15 aa with an offset of three amino acids (Supporting Information Table S7 ). The peptides come tethered to the membrane support via their Ctermini. The array was incubated with MBP-PavA or SSURE 2 1 3 , and bound ligand was visualized. When the peptides were only incubated with the antibodies as a control, positive reactions were observed (Supporting Information Fig. S4 ). After background subtraction, the spots above a threshold level (difference of 1000 RU between overlay and control spot) were considered as significant, marked and quantified by Image J. 
Visualization of PavA and PavB binding epitopes in FnIII repeats
To visualize the distribution of the bound peptides, threedimensional structures of FnIII domains were taken from the PDB or modelled based on the structure of Fibcon, which has a synthetic Fn consensus sequence (Jacobs et al., 2012) . Due to pairwise sequence identities of more than 30%, missing structures can be sensibly modelled. All structures could be superimposed onto FnIII 7 with a root mean square deviation on Cas of less than 1.4 Å (except the experimental models obtained by NMR: FnIII 1 2.2 Å , FnIII 12 1.8 Å ). The recognized epitopes cluster on regions 15-35 (b-strands B and C) and 67-69 (b-strand F, numbering of Fibcon, residues recognized 9 times or more by SSURE 2 1 3 or PavA). The electrostatic surfaces of the repeats ( Fig. 7 and Supporting Information Fig.  S5 ) show no common pattern. Nevertheless, charge does play a role in binding as can be seen in the recognition propensities, i.e. the preference of certain amino acid types to occur in the recognized peptides compared with the complete sequence ( Fig. 7 and Supporting Information Fig. S6 ). In the peptide array, the immobilized peptides are not structured and all residues assumed to be equally accessible to the probe. As this is not true for the native FnIII repeats, the binding propensities were calculated for solvent accessible residues (buried residues were taken from (Jacobs et al., 2012) ). Smaller hydrophobic and neutral hydrophilic amino acids show no preference. Acidic amino acids and larger hydrophobic ones are bound less often, basic amino acids more often than expected based on their frequency in the FnIII repeats (Supporting Information Fig. S6 ). Cys and Trp are not or only once on the surface, therefore, no propensities are given for these residues. The majority of the epitopes are located on b-strands B, C and F and the AB-and BC-loop. These are the strands in the centre of the 3-stranded and 4-stranded bsheets, whereas the more flexible b-sheet edges are rarely bound to. In those experimental structures showing the arrangement of neighbouring FnIII repeats, the Cterminal tip of one domain contacts the N-terminal end of the next domain on the side of the 4-stranded b-sheet. The well-recognized b-strand connections AB-loop and BC-loop are therefore accessible (Figs 7 and 8A ).
Binding of FnIII peptides to pneumococcal FnBPs PavA and PavB
To analyze whether positive peptide sequences of the array indeed interact with PavA and PavB, respectively, six peptides were synthesized and employed in binding assays using SPR. FnBPs, immobilized on the CM5 biosensor, were incubated with increasing amounts of peptides derived from Table S10 ).
In conclusion, the direct binding assays indicated the function of identified short FnIII peptides for the interaction with pneumococcal FnBPs, which contain basic amino acids and have a more basic pI (Fig. 9 ).
Discussion
Streptococcus pneumoniae is a pathobiont of the human nasopharyngeal microbiome exploiting a diverse repertoire of its virulence factors to successfully maintain its commensal or even pathogenic status. A major strategy is the engagement of proteinaceous MSCRAMMS (Paterson and Orihuela, 2010; Voss et al., 2012) to interact with host adhesive glycoproteins such as fibronectin. Our study reveals to our knowledge for the first time the ability of pneumococci to acquire speciesindependent soluble Fn from plasma, indicating its ability to interact with Fn not only as a part of ECM but also as part of the serum. Several Gram-positive bacteria like S. aureus and S. pyogenes use fibronectin as a molecular bridge to interact with host eukaryotic cells via cellular integrin a 5 b 1 (Talay et al., 2000; Ingham et al., 2004) . Pneumococci are reported to exploit cell-bound human vitronectin, Factor H, human thrombospondin and Fn as molecular bridge, thereby linking the bacterium with the eukaryotic cell and enhancing adherence (Rennemeier et al., 2007; Yamaguchi et al., 2008; Bergmann et al., 2009; Agarwal et al., 2010) . This study confirms the ability of pneumococci to exploit fibronectin, in a species-unspecific manner, as molecular bridge leading to enhanced adherence to the host cells independent of the cell type.
Pneumococcal FnBPs documented so far include PavA, PavB, PfbA, PfbB and endopeptidase O (Paterson and Orihuela, 2010; Voss et al., 2012) . Our study focuses on FnBPs PavA and PavB, representing diverse molecules with respect to their primary sequence and molecular organization. Far western ligand overlay assays with human plasma Fn and SPR studies suggest that both PavA proteins (full-length PavA and PavA 42 ) and PavB (SSURE 2 1 3 ) interact with plasma Fn and purified Fn as well as FnIII repeats. Thus, our results deciphered the mechanism of how PavA and PavB interact with Fn and its FnIII repeats. In an earlier study PavA 42 has been reported to lack the ability to interact with immobilized Fn (Holmes et al., 2001) , while this study suggests also the interaction with Fn via the extended N-terminal part of PavA, PavA 42 . This construct covers the N-terminal half of PavA and the following long helix of the C-terminal half (Supporting Information Fig. S1 ). The N-terminal half of the PavA homolog FBPS of Streptococcus suis, FBPS-N, is properly folded, which should thus be true for PavA-N as well. It was not determined if the exposed helix folds, however, precipitation of PavA 42 as expected for unstructured proteins has not been observed. The different binding behaviour between PavA and PavA 42 could thus lie in the C-terminal 186 residues or in an improperly folded helix of PavA 42 . FBPS of S. suis interacts via its C-terminal part FBPS-C with the N-terminal 30 kDa part of Fn when used in micromolar concentrations in surface plasmon resonance studies (Musyoki et al., 2016) . FBPS-N did not bind to the N-terminal part of Fn. However, binding of FBPS to FnIII repeats has not been tested and therefore it is still unknown whether the PavA homolog has the capacity to interact also with FnIII repeats. 1910 -1936 RFLATTPNSLLVSWQPPRARITGYIIK 3138.8 11.72 FnIII15 1970 -1991 TIYVIALKNNQKSEPLIGRKKT 2554 PavB is characterized by its repetitive SSURE domains , while such repetitive attributes are not present in pneumococcal PavA (Holmes et al., 2001) . PavB is a multifunctional adhesin molecule, interacting directly with a yet unknown cellular receptor, but interacts in addition with Fn further with plasminogen and thrombospondin Binsker et al., 2015) . The binding activities of PavB depend on the number of SSURE domains and accordingly, this study indicates that a decreasing number of SSURE reduces the binding efficiency, supported by a negligible binding of soluble Fn for the single repeat SSURE 2 . The crucial role of repetitive elements of pneumococcal PavB and PspC was also indicated for the interaction with human thrombospondin (both PavB and PspC) (Binsker et al., 2015) and vitronectin (only PspC) (Voss et al., 2013) , strengthening the concept that repetitive elements of bacterial proteins play a pivotal role in determining their function and activity (Lin et al., 2012) .
The structural characteristics of a typical monomer of Fn include the repetitive elements each type repeat having an independent three-dimensional modular structure with multiple binding sites for various biological ligands, thereby endowing this macromolecule with a huge functional versatility (Pankov and Yamada, 2002; Henderson et al., 2011) . Bacterial FnBPs exploit the structural dynamics of Fn to colonize host eukaryotic cells and to enhance their pathogenicity potential (Sinha et al., 1999; Talay et al., 2000; Edwards et al., 2010) . While FnBPs of Gram-positive bacteria such as S. aureus (FnBPA/B) (Ingham et al., 2004) and S. pyogenes (SfbI) (Talay et al., 2000) or of Gram-negative B. burgdorferi (BBK32) (Probert and Johnson, 1998; Kim et al., 2006) bind to the N-terminal type I and type II Fn repeats by using a tandem b-zipper model, pneumococcal FnBPs differ most likely in this regard. The Fn interaction of PavA with Fn is heparin sensitive (Holmes et al., 2001) suggesting the involvement of heparin binding domain(s) of Fn. For PavB Bumbaca and colleagues hypothesized that FnIII repeats are targeted because the inter-domain distance of 41 Å between SSURE domains is similar to the 45 Å distance between consecutive FnIII repeats as compared with the N-terminal FnI repeats showing a distance of 22 Å (Bumbaca et al., 2004) .
In agreement with this assumption, our study indicates binding of pneumococcal PavA, PavA 42 and PavB (SSURE 2 1 3 ) to FnIII repeats, while binding to the 70 kDa N-terminal Fn domains was negative (Fig. 9) . The interaction patterns of PavA and PavA 42 with FnIII show some variability, which depends on the experimental approach. SPR analysis demonstrated negligible interaction of PavA and SSURE 2 1 3 with FnIII 7-10 , while far western dot blots imply considerable interaction between these two interacting partners. For PavB no interaction region was reported for encompasses the typical heparin binding domain II (HBDII) of fibronectin, which is essential for Fn multimerization (Mitsi et al., 2008) and assists the central cellbinding domain (CCBD) to interact with a 5 b 1 integrin (Kim et al., 2006) . Considering the biological function of both of these stretches of FnIII repeats, it is logical to speculate that pneumococcal FnBPs might exploit the individual function of these repeats to interact with host eukaryotic cells via the integrin route. Consequently, pneumococcal PavA and PavB did not recognize the amino acids in the critical motif RGD (FnIII10) and the synergistic motifs PHSRN (FnIII 9 ) (only PavA) (Aota et al., 1994) and KNEED (FnIII 8 ) (Wong et al., 2002) .
These regions are employed by human Fn to interact directly with a 5 b 1 integrin.
Binding of PavA and PavB to FnIII repeats was further analyzed with regard to amino acid composition and location of the bound epitopes. The bound epitopes preferably contain basic amino acids, but disfavour acidic and larger hydrophobic residues. Consequently, the negatively charged motif KNEED in FnIII 8 is not bound. Competition of heparin and PavA for the same binding sites on Fn also fits to these preferences. The negatively charged heparin likely binds to basic amino acids as do PavA and PavB. Despite the large number of recognized surface residues of FnIII domains (more than 400 for PavA and PavB together), no amino acid pattern or even specific recognition sequence emerges. It should be emphasized at this point that the peptides presented on the membrane are too short for building stable three-dimensional structures, which are present in the native structure of the FnIII domains. In addition the interaction studies with these short peptides cannot represent the in vivo interaction of pneumococcal FnBPs with folded human fibronectin. Additionally, no structural information on the glycosylation of these domains is available to date. Topologically, the epitopes cluster on the inner strands of both b-sheets, which form the fibronectin domain. The bordering/outer strands are less well recognized in contrast to the FnI domains where the edges of b-sheets of two neighbouring domains bind a streptococcal FnBP peptide via a tandem b-zipper (Schwarz-Linek et al., 2003) . This analysis has the caveat that binding to peptides is used to model the location of binding epitopes on folded FnIII domains. Direct structural confirmation is missing. The unfolded state of FnIII domains, on the other hand, is not completely unphysiological. FnIII domains can spontaneously unfold exposing b-strands otherwise in the interior of b-sheets (Ohashi and Erickson, 2005) . Also, mechanical tension partially unfolds FnIII domains exposing cryptic sites and enabling new b-strand interactions required and observed during fibrillogenesis (Gao et al., 2003) . Some of the regions recognized by the FnBPs were synthesized as short peptides and these peptides were tested individually for their capacity to interact directly with immobilized pneumococcal PavA and PavB via SPR. Indeed, four of the six peptides (FnIII 1 634-651, [1823] [1824] [1825] [1826] [1827] [1828] [1829] [1830] [1831] [1832] [1833] [1834] showing no positive interaction with PavA and PavB, respectively, are neutral or even negatively charged. In addition these peptides are shorter than the positively tested peptides. This point to a pivotal role of basic amino acids in FnIII repeats to interact with FnBPs. Remarkably, this fits perfectly to the interaction of PavB with plasminogen .
In conclusion, the identified direct binding of these FnIII peptides may thus find an application not only for these peptides as antimicrobial agents specifically for S. pneumoniae but also for other Gram-positive andnegative bacteria targeting FnIII repeats by their respective FnBPs to combat colonization and invasive infections. In fact, one of these peptides, namely FnIII 15 1910-1936, has indeed been confirmed earlier for its antimicrobial potential against some Gram-positive and -negative bacteria (Andersson et al., 2004; Malmsten et al., 2006) .
Experimental procedures
Bacterial strains and culture conditions Streptococcus pneumoniae serotype 35A (NCTC10319) was grown on blood agar plates (Oxoid, Wesel, Germany) or in Todd-Hewitt-broth (Roth, Karlsruhe, Germany) supplemented with 0.5% yeast extract (THY) to mid-log phase at 378C and 5% CO 2 . In adherence studies the pneumolysin-negative isogenic mutant was used (Pracht et al., 2005) .
Cell lines and cell culture
The human lung alveolar carcinoma epithelial cell line A549 (ATCC CCL-185) and HEp-2 larynx carcinoma cell line (ATCC CCL-23) were cultured in Dulbecco's modified Eagle's medium (DMEM, PAA) containing 10% fetal bovine serum (FBS, PAA), 2 mM glutamine, penicillin (100 Units/ ml) and streptomycin (0.1 mg/ml). The human pharynx carcinoma cell line Detroit 562 (ATCC CCL-138) was cultured in RPMI 1640 supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, penicillin (100 Units/ml) and streptomycin (0.1 mg/ml). Prior to infections (48 h), cells were seeded at a density of 5 3 10 4 cells per well in 24-well plates (Greiner). All cells were cultured at 378C in 5% CO 2 .
Reagents and antibodies
Human plasma fibronectin was obtained from Invitrogen or Cambridge Bioscience (UK), human cellular fibronectin was received from Biomol. The N-terminal 70 kDa Fn fragment, bovine plasma fibronectin, goat anti-rabbit IgG conjugated with either Alexa Fluor 488 or Alexa Fluor 568 were purchased from Sigma. Polyclonal anti-fibronectin IgG was from Dako. Secondary antibodies conjugated with peroxidase were obtained from Jackson ImmunoResearch. Rabbit anti-pneumococcal antiserum was generated by Eurogentec (Pracht et al., 2005) . Goat anti rabbit IgG conjugated with alkaline phosphatase was from Abcam while streptavidin-alkaline phosphatase conjugated antibody was purchased from Millipore. 
Expression and purification of fusion proteins
The recombinant SSURE domains and 42 kDa N-terminal domain of PavA (PavA 42 ) used in this study were expressed and purified as described earlier (Holmes et al., 2001; Pracht et al., 2005; Jensch et al., 2010) . Full-length PavA was expressed and purified as an MBP fusion (Pracht et al., 2005) . His 6 -tagged recombinant FnIII domains were expressed in Escherichia coli as reported earlier (Ohashi and Erickson, 2005) . His 6 -tagged proteins were purified by immobilized metal affinity chromatography (IMAC) employing HiTrap Ni-NTA columns (GE Healthcare) following manufacturer's instructions. All the proteins were analyzed for their integrity and purity by SDS-PAGE and Coomassie brilliant blue (CBB) or silver staining.
Binding of soluble fibronectin to pneumococci
To detect binding of Fn by pneumococci a flow cytometric analysis was conducted after incubating 10 8 cfu with human or plasma from different animal species (kindly provided by Ulrike Blohm, Friedrich-Loeffler Institut, Island Riems, Germany), FBS (PAA or Gibco) or purified human plasma (Invitrogen), cellular (Biomol) or bovine plasma (Sigma) fibronectin in indicated amounts in a volume of 100 ml for 30 min at 378C. Pneumococci were washed once in PBS and incubated with rabbit anti-fibronectin antibody (Dako) diluted 1:300 for 30 min at 378C. After washing the bacteria with PBS secondary FITC-labelled goat anti-rabbit Ig (Dianova/Jackson ImmunoResearch) diluted 1:300 was added for 30 min at 378C. Pneumococci were fixed with 1% paraformaldehyde for 1 h at 48C and Fn binding was analyzed using a FACSCalibur cytometer (Becton Dickinson).
To detect pneumococci-bound Fn by immunoblot analysis 2 3 10 9 cfu were incubated in a volume of 100 ml with plasma of different species (human, cow, pig, alpaca, goat and weasel), FBS (PAA), indicated amounts of fibronectin or PBS as control for 30 min at 378C. After washing the bacteria once with PBS, transfer in a new 1.5 ml tube, equal amounts of samples were separated in a SDS-PAGE under reducing conditions, blotted on PVDF membranes (Millipore) using a semi-dry blotting system (Biorad) and blocked with 1% skim milk (Roth). Plasma (0.25 ml) and purified fibronectin (0.1 mg) were applied as positive controls. Fn was detected using rabbit anti-fibronectin IgG (Dako) diluted 1:1000 followed by incubation with alkaline phosphatase labeled goat anti-rabbit Ig (Dianova/Jackson Immuno Research and finally the membrane was developed by using suitable substrates (NBT and BCIP).
Adherence assays
Pneumococcal adherence studies were performed in 24-well tissue culture plates (Greiner, Germany) as described previously (Pracht et al., 2005) . Eukaryotic cells were incubated in some experiments with indicated amounts of purified fibronectin for 45 min. To conduct adherence studies only in the presence of host cell bound Fn, unbound Fn was removed by washing the cells with DMEM HEPES/1% FBS. Infections were performed with 5 3 10 6 pneumococci grown in THY medium to an OD 600 of 0.3 to 0.4. In other adherence experiments 5 3 10 6 bacteria were preincubated with 5 mg human fibronectin for 20 min at 378C and these bacteria were used in the adherence studies. After 4 h of incubation at 378C in 5% CO 2 , non-adherent bacteria were removed by rinsing several times the wells with phosphate buffered saline (PBS), the host cells and bacteria were fixed with 1% PFA and bacteria were stained for immunofluorescence microscopy as described (Pracht et al., 2005) .
Far-western ligand overlay
To analyze the interaction of pneumococcal proteins with human Fn under native conditions, far western ligand overlay assays were conducted.
Human Fn, the 70kDa N-terminal proteolytic fragment (Sigma) and His 6 -FnIII domains were immobilized on a nitrocellulose membrane (NC). Non-specific binding was blocked by treatment of the NC with 5% skimmed milk (Roth), followed by PBS washing steps and the incubation with the specific ligands (MBP-PavA, biot-SSURE 2 1 3 and biot-PavA 42 ) overnight at 48C. Unbound ligands were removed in washing steps with PBS-Tween (0.05%) and bound biotinylated ligands (biot-PavA 42 and biot-SSURE 2 1 3 ) were detected with a streptavidin-alkaline phosphatase conjugated antibody (Millipore) at a dilution of 1:5000. Bound MBP-PavA was detected with anti-rabbit anti-PavA IgG (1:500) followed by a goat anti-rabbit IgG conjugated with alkaline phosphatase. In a reverse approach pneumococcal recombinant proteins were spotted on NC and after blocking with 5% skimmed milk (Roth) the membrane was incubated overnight at 48C with human plasma (obtained from healthy individuals upon their informed consent). After extensive washing with PBSTween (0.05%) the NC was incubated for 1 h at RT with the specific antibodies for human fibronectin (1:1000, Dako). Binding of the primary antibody was detected after two washing steps with PBS using a secondary antibody conjugated with alkaline phosphatase (1:5000) followed by incubation with the specific substrate 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (NBT/BCIP). The reaction was finally stopped with PBS.
Surface plasmon resonance studies
To analyze directly protein-protein interactions without using antibodies the SPR technique was employed using a BiacoreT100 optical biosensor as described Binsker et al., 2015; Kohler et al., 2015) . Binding of MBP-PavA (full-length PavA), MBP (control), PavA 42 (His 6 -PavA 42 ) or PavB (His 6 -SSURE 2 1 3 ) to human Fn and Fn domains, respectively, was investigated to immobilized Fn and recombinant His 6 -tagged Fn domains. Briefly, 10 mg/ml of Fn (10mM sodium acetate buffer pH 4.0) or 10 mg/ml of the 70 kDa proteolytic N-terminal domain of Fn (10 mM sodium acetate, pH 4.5), FnIII domains FnIII 1-5 (10 mM sodium acetate, pH 4.5), FnIII 4-7 (10 mM sodium acetate, pH 5.0), FnIII 7-10 (10 mM sodium acetate, pH 5.5), FnIII [12] [13] [14] (10 mM sodium acetate, pH 4.5) and FnIII 13-15 (10 mM sodium acetate, pH 5.0), respectively, were coupled on a carboxymethyl dextran (CM5) biosensor at a flow rate of 10 ml/min onto the N-hydroxysuccinimide (NHS)/N-ethyl-N 0 -(3-dimethylaminopropyl) carbodiimide (EDC) (NHS 0.5M and EDC 0.2 M) activated CM5 biosensor (70 ml, 10 ml/min). For FnIII 10-12 a concentration of 25mg/ml (10 mM sodium acetate, pH 4.5) was used. Control flow cells were also activated but without injecting the specific protein. Binding of PavA/ PavB analytes was performed in PBS-Tween (0.05%) (pH 7.4) at 258C at a flow rate of 10 ml/min in all experiments. The affinity surface was regenerated between subsequent sample injections of SSURE 2 1 3 and PavA 42 proteins with 10 ml of 12.5 mM NaOH. In the vice versa approach MBPPavA, MBP, His 6 -PavA 42 and His 6 -SSURE 2 1 3 were immobilized on the CM5 biosensor and Fn domains used as analytes. Here, 25 mg/ml of MBP-PavA (10 mM sodium acetate, pH 4.0), 25 mg/ml of MBP (10 mM sodium acetate, pH 4.0), 10 mg/ml of His 6 -PavA 42 (10 mM sodium acetate, pH 4.0) and 10 mg/ml of His 6 -SSURE 2 1 3 (10 mM sodium acetate, pH 5.5) were coupled to the CM5 biosensor. Each interaction was measured at least three times. The sensorgrams represent the values of the response units (RU) after subtraction of the blank run and value(s) without analyte protein(s) from the corresponding sensorgrams. Data were analyzed using BiacoreT100 Evaluation Software (version 2.0.1.1).
SPOT peptide array analysis
To delineate the interaction of pneumococcal FnBPs with FnIII domains down to the amino acid level, a SPOT peptide array was generated and used in ligand overlay assays. The complete sequence of the FnIII region (Supporting Information Table S5 ) was divided into 445 peptides consisting of 15 amino acids each with an overlap of 12 amino acids (shift of three aa). The peptides were synthesized as array of spots on aminopegylated cellulose membrane (AIMS Scientific Products GmbH, Germany) as described (Frank, 1992; Bergmann et al., 2003) . After final assembly and deprotection of the amino acid side chains, the membrane was blocked over a period of 1-2 days with twofold casein containing-blocking reagent (Sigma). Thereafter the membrane was incubated with the specific ligand (MBPPavA or His 6 -SSURE 2 1 3 ) overnight at 48C. Bound ligands were detected by using specific anti sera against PavA (rabbit anti-PavA) (Noske et al., 2009) and PavB (mouse anti-PavB) followed by the secondary antibody (goat antirabbit in case of PavA and goat anti-mouse in case of PavB) conjugated with peroxidase (1: 5000) and chemiluminescence reagent and H 2 O 2 as substrate. In control experiments the membranes were incubated only with primary and secondary antibodies.
Visualization of PavA and PavB binding sites
To map the epitopes identified in epitope mapping onto the surface of the three-dimensional structure of the FnIII repeats, known structures were used as supplied by the PDB. Repeats whose structure has not been determined were modeled with Swiss-Model (Biasini et al., 2014) . An alignment of all 15 repeats has been described and the structure of its consensus sequence, called Fibcon, solved to high resolution (Jacobs et al., 2012 (Cohen, 1997) . Surfaces with either the electrostatic potential (red negative, blue positive; Supporting Information Fig. S2 ) or the PavA-and PavB-binding epitopes (Fig. 6) were created with CCP4MG (McNicholas et al., 2011) . For calculating the binding propensities of each amino acid aa the number of residues in all FnIII repeats aa all and those in the recognized epitopes aa bound , taking into account only those residues that are not buried (Jacobs et al., 2012) , were counted and compared with the total numbers n all and n bound :
propensity aa ð Þ5 n all aa bound n bound aa all
Field emission scanning electron microscopy (FESEM)
Samples were fixed with 2% glutaraldehyde and 5% formaldehyde in cacodylate buffer (0.1 M cacodylate, 0.01 M CaCl 2 , 0.01 M MgCl 2 , 0.09 M sucrose, pH 6.9) on ice and sent in the fixative. After washing with cacodylate buffer cover slips were then washed with TE-buffer (20 mM TRIS, 1 mM EDTA, pH 6,9) before dehydrating in a graded series of acetone (10%, 30%, 50%, 70%, 90%, 100%) on ice for 15 min for each step, critical-point dried with liquid CO 2 (CPD 30, Balzers, Liechtenstein) and covered with a gold film by sputter coating (SCD 40, Balzers Union, Liechtenstein) before examination in a field emission scanning electron microscope (Zeiss DSM 982 Gemini) using the Everhart Thornley SE-detector and the inlens SE-detector in a 50:50 ratio at an acceleration voltage of 5 kV. Images were recorded onto a MO-disk and contrast and brightness were adjusted using Adobe Photoshop 5.0.
Statistical analysis
Data were expressed as mean 6 SD and differences in adherence and invasion, respectively, were analyzed by the two-tailed unpaired Student's t-test. A value of p < 0.05 was considered statistically significant.
